Preclinical and In Vivo Research Tools

Preclinical research bridges the gap between target-focused and cell-based screening and eventual clinical testing. It encompasses both advanced in vitro models that better approximate tissue-level biology and in vivo studies conducted in animal models to characterize efficacy, pharmacokinetics, and toxicity within a living system. This stage is widely regarded as a critical checkpoint in drug development, as compounds that perform well in simple monolayer or biochemical assays often fail once tested against more physiologically complex systems.

Preclinical characterization typically begins with three-dimensional cell culture models, such as spheroids and organoids, which allow researchers to assess compound activity in a tissue-like architecture before committing to animal studies. Promising candidates are then evaluated using histological and immunohistochemical techniques to localize target expression and assess tissue-level effects across relevant organ systems. Compounds that clear these stages advance to in vivo studies in appropriate animal models, where behavioral, physiological, and imaging-based endpoints are collected to characterize efficacy and safety within a whole organism. Together, these methods provide a tiered body of evidence that supports the decision to advance a candidate toward regulatory filing and clinical trials. Highlighted below are key product categories that support preclinical and in vivo research.

Essential Tools and Techniques

• 3D cell culture models, including spheroid and organoid culture media, cell culture hydrogels, basement membrane extracts, cell culture inserts, and ultra-low attachment plates and dishes, allow researchers to grow cells in a configuration that better recapitulates in vivo tissue architecture than standard monolayer culture. 3D bioprinters and other dedicated 3D cell culture tools are increasingly used to build more complex, multi-cell-type constructs for this purpose.
• Histology and immunohistochemistry (IHC) tools, including IHC kits, antibodies, reagents, and stains, along with supporting histology equipment, allow researchers to visualize target expression and tissue morphology in fixed sections from both in vitro and in vivo studies. Blood and tissue products, tissue lysates, and protein conjugation and labeling reagents support sample preparation and detection chemistry, while histology and IHC services offer a contracted route for labs without in-house sectioning or staining capacity.
• Animal models remain the standard system for evaluating compound efficacy, pharmacokinetics, and toxicity within an intact, living organism, as no in vitro system fully captures the systemic interactions between organs, immune function, and metabolism that govern drug response.
• Animal behavior and physiological monitoring equipment, including animal blood pressure monitoring systems allow researchers to quantify pain, respiratory function, and other physiological endpoints in a standardized, minimally invasive manner. Supporting hardware, such as catheters, syringe infusion pumps, and general animal handling equipment, is typically needed to administer compounds and maintain animal welfare throughout a study.
• In vivo imaging systems permit longitudinal, non-invasive tracking of tumor growth, biodistribution, or other disease-relevant endpoints within the same animal over time, an approach that can reduce the number of animals needed per study relative to endpoint-only designs.
• Neuroscience and electrophysiology equipment, including micromanipulation equipment and electrophysiology recording systems, supports detailed characterization of neural activity and circuit-level function in animal models, a capability that is often central to central nervous system-focused drug development programs.

Prospective buyers should consider how closely a given preclinical model needs to approximate human physiology for the question at hand, as more complex 3D or in vivo systems generally come at the cost of lower throughput and higher per-study expense. Sequencing simpler in vitro models ahead of animal studies, rather than relying on either approach alone, remains the most common strategy for balancing predictive value against cost and animal use.